Expression and functional evaluation of biopharmaceuticals made in plant chloroplasts

Zhang, Bei; Shanmugaraj, Balamurugan; Daniell, Henry

doi:10.1016/j.cbpa.2017.02.007

Cited by 55 publications

(40 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most powerful is transient expression following Agrobacterium-mediated gene transfer into host plants via RNA virus-mediated RNA amplification or DNA virus-based gene amplification. Another important approach is chloroplast transformation, which integrates the target gene into the chloroplast genome and thereby leads to extremely high levels of protein production (Staub et al, 2000;Verma and Daniell, 2007;Zhang et al, 2017); the transgenic approach, which integrates foreign genes into the plant nuclear genome, is also widely used (Lee et al, 2015;Sohn et al, 2018;Twyman et al, 2002). Many different strategies using transgenic plants can be employed as recombinant proteins can be obtained from either whole plants or cell cultures (Holtz et al, 2015; Rosales-Mendoza and Nieto-G omez, 2018;Tekoah et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Islam

Kwak

Lee

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Plants have recently received a great deal of attention as a means of producing recombinant proteins. Despite this, a limited number of recombinant proteins are currently on the market and, if plants are to be more widely used, a cost‐effective and efficient purification method is urgently needed. Although affinity tags are convenient tools for protein purification, the presence of a tag on the recombinant protein is undesirable for many applications. A cost‐effective method of purification using an affinity tag and the removal of the tag after purification has been developed. The family 3 cellulose‐binding domain ( CBM 3), which binds to microcrystalline cellulose, served as the affinity tag and the small ubiquitin‐related modifier ( SUMO ) and SUMO ‐specific protease were used to remove it. This method, together with size‐exclusion chromatography, enabled purification of human interleukin‐6 ( hIL 6) with a yield of 18.49 mg/kg fresh weight from leaf extracts of Nicotiana benthamiana following Agrobacterium ‐mediated transient expression. Plant‐produced hIL 6 (P‐ hIL 6) contained less than 0.2 EU/μg (0.02 ng/mL) endotoxin. P‐ hIL 6 activated the Janus kinase‐signal transducer and activator of transcriptional pathways in human LNC aP cells, and induced expression of IL ‐21 in activated mouse CD 4 + T cells. This approach is thus a powerful method for producing recombinant proteins in plants.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Islam

Kwak

Lee

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…Currently, countries, including Thailand, India, Japan, Korea, and the European community, are majorly involved in developing plant biopharmaceuticals against several human diseases [21]. Many reports reviewed the importance of plant expression system for the rapid production of candidate vaccines and therapeutic antibodies against infectious diseases [22][23][24][25][26][27]. Table 2.…”

Section: Perspectives On Biopharmaceuticals Developmentmentioning

confidence: 99%

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

2020

Self Cite

View full text Add to dashboard Cite

Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified in Wuhan, China in late December 2019. This virus is responsible for the ongoing outbreak that causes severe respiratory illness and pneumonia-like infection in humans. Due to the increasing number of cases in China and outside China, the WHO declared coronavirus as a global health emergency. Nearly 35,000 cases were reported and at least 24 other countries or territories have reported coronavirus cases as early on as February. Inter-human transmission was reported in a few countries, including the United States. Neither an effective anti-viral nor a vaccine is currently available to treat this infection. As the virus is a newly emerging pathogen, many questions remain unanswered regarding the virus's reservoirs, pathogenesis, transmissibility, and much more is unknown. The collaborative efforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the proper diagnostic tools, and effective treatment to combat this infection. Recent advancements in plant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals rapidly in a short time. In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine development, and the potential of a plant system for biopharmaceutical development are discussed.

show abstract

Section: Most Therapeutic Proteins Are Produced In Either Chinesementioning

confidence: 99%

“…While plants have not been used extensively to produce therapeutic protein products in the past, there is a history of genetically engineering plants to produce useful compounds (Vasil, ), and a wealth of knowledge in the scientific literature about genetic engineering in crop plants and tobacco in particular (Shinozaki et al, ; Zhang, Shanmugaraj, & Daniell, ; Zhang, Li, et al, ). Plants have been previously considered as expression systems for therapeutic recombinant proteins, and the concept is gathering steam again as scientists look to increase the efficiency of producing recombinant proteins (Kaiser, ; Tekoah et al, ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic recombinant protein production in plants: Challenges and opportunities

Burnett¹,

Burnett

2019

Plants People Planet

164

105

View full text Add to dashboard Cite

Societal Impact Statement Therapeutic protein production in plants is an area of great potential for increasing and improving the production of proteins for the treatment or prevention of disease in humans and other animals. There are a number of key benefits of this technique for scientists and society, as well as regulatory challenges that need to be overcome by policymakers. Increased public understanding of the costs and benefits of therapeutic protein production in plants will be instrumental in increasing the acceptance, and thus the medical and veterinary impact, of this approach. Summary Therapeutic recombinant proteins are a powerful tool for combating many diseases which have previously been hard to treat. The most utilized expression systems are Chinese Hamster Ovary cells and Escherichia coli, but all available expression systems have strengths and weaknesses regarding development time, cost, protein size, yield, growth conditions, posttranslational modifications and regulatory approval. The plant industry is well established and growing and harvesting crops is easy and affordable using current infrastructure. Growth conditions are generally simple: sunlight, water, and the addition of cheap, available fertilizers. There are multiple options for plant expression systems, including species, genetic constructs and protein targeting, each best suited to a particular type of therapeutic protein production. Transient expression systems provide a mechanism to rapidly transfect plants and produce therapeutic protein in a matter of weeks, rather than the months it can take for many competing expression systems, while proteins targeted to cereal seeds can be harvested, stored and potentially purified much more easily than in competing systems. Current challenges for plant expression systems include a lack of regulatory approval, environmental containment concerns and nonhuman glycosylation, which may limit the scope of the type of therapeutic proteins that can be manufactured in plants. The specific strengths of plant expression systems could facilitate the production of certain therapeutic proteins quickly and cheaply in the near future.

show abstract

Expression and functional evaluation of biopharmaceuticals made in plant chloroplasts

Cited by 55 publications

References 54 publications

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

Therapeutic recombinant protein production in plants: Challenges and opportunities

Contact Info

Product

Resources

About